NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma to Begin Trading on American Stock Exchange
Tomorrow 


FLEMINGTON, N.J., May 10  /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. 
(BULLETIN BOARD: NVDL)  today announced that its common stock is expected to
begin trading on the American Stock Exchange starting with the opening of the
market tomorrow, May 11, 2004, under the symbol NVD.

NovaDel's chief executive officer Gary A. Shangold, MD, said, "we are delighted
about obtaining listing privileges on the American Stock Exchange and look
forward to the benefits it will bring to our current and future shareholders in
increasing our visibility and liquidity in the capital markets."

NovaDel is a leading formulator of lingual spray drugs for systemic delivery
through the oral mucosa to effect rapid onset of action and reduced toxicity. 
It plans to file for US FDA approval of it first product, lingual spray
nitroglycerin, by the end of next month.  Plans for feasibility studies of five
other drugs, which are currently marketed in other formulations, are well
underway.

Later this week, on Wednesday, May 12, NovaDel will be presenting at the Rodman
& Renshaw TechVest Global Healthcare Conference (May 12-14), Claridge's Hotel,
London, England, at 9:25am BST, British Summer Time (4:25 am EDT). A webcast of
the presentation will be available on the date of the presentation and will be
archived for 90 days.  For details go to http://www.rodmanandrenshaw.com/.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and
over-the-counter drugs. The Company's proprietary lingual spray technology
delivery system offers the patient (i) fast onset of action; (ii) improved drug
safety by reducing the required drug dosage and reducing side effects; (iii)
improved patient convenience and compliance; and (iv) enhanced dosage
reliability. The Company plans to develop such products independently and
through collaborative arrangements with major pharmaceutical and biotech
companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain FDA
and other regulatory approvals for products under development. Further, the
Company operates in industries where securities may be volatile and may be
influenced by regulatory and other factors beyond the Company's control.
Important factors that the Company believes might cause such differences are
discussed in the risk factors detailed in the Company's most recent Annual
Report and Registration Statements, filed with the Securities and Exchange
Commission. In assessing forward-looking statements contained herein, if any,
the reader is urged to carefully read all cautionary statements contained in
such filings. 

DATASOURCE: NovaDel Pharma Inc.



CONTACT:  Barry C. Cohen, VP New Business & New Product Development of

NovaDel Pharma Inc., [phone] x 2160; Thomas Redington,

[phone], [phone], , for NovaDel

Pharma Inc. 



Web site:  http://www.rodmanandrenshaw.com/ 

Copyright